Cargando…
A Methodological Safe-by-Design Approach for the Development of Nanomedicines
Safe-by-Design (SbD) concepts foresee the risk identification and reduction as well as uncertainties regarding human health and environmental safety in early stages of product development. The EU’s NANoREG project and further on the H2020 ProSafe initiative, NanoReg2, and CALIBRATE projects have dev...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145422/ https://www.ncbi.nlm.nih.gov/pubmed/32300587 http://dx.doi.org/10.3389/fbioe.2020.00258 |
_version_ | 1783519997899833344 |
---|---|
author | Schmutz, Mélanie Borges, Olga Jesus, Sandra Borchard, Gerrit Perale, Giuseppe Zinn, Manfred Sips, Ädrienne A. J. A. M Soeteman-Hernandez, Lya G. Wick, Peter Som, Claudia |
author_facet | Schmutz, Mélanie Borges, Olga Jesus, Sandra Borchard, Gerrit Perale, Giuseppe Zinn, Manfred Sips, Ädrienne A. J. A. M Soeteman-Hernandez, Lya G. Wick, Peter Som, Claudia |
author_sort | Schmutz, Mélanie |
collection | PubMed |
description | Safe-by-Design (SbD) concepts foresee the risk identification and reduction as well as uncertainties regarding human health and environmental safety in early stages of product development. The EU’s NANoREG project and further on the H2020 ProSafe initiative, NanoReg2, and CALIBRATE projects have developed a general SbD approach for nanotechnologies (e.g., paints, textiles, etc.). Based on it, the GoNanoBioMat project elaborated a methodological SbD approach (GoNanoBioMat SbD approach) for nanomedicines with a focus on polymeric nanobiomaterials (NBMs) used for drug delivery. NBMs have various advantages such as the potential to increase drug efficacy and bioavailability. However, the nanoscale brings new challenges to product design, manufacturing, and handling. Nanomedicines are costly and require the combination of knowledge from several fields. In this paper, we present the GoNanoBioMat SbD approach, which allows identifying and addressing the relevant safety aspects to address when developing polymeric NBMs during design, characterization, assessment of human health and environmental risk, manufacturing and handling, and combines the nanoscale and medicine field under one approach. Furthermore, regulatory requirements are integrated into the innovation process. |
format | Online Article Text |
id | pubmed-7145422 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71454222020-04-16 A Methodological Safe-by-Design Approach for the Development of Nanomedicines Schmutz, Mélanie Borges, Olga Jesus, Sandra Borchard, Gerrit Perale, Giuseppe Zinn, Manfred Sips, Ädrienne A. J. A. M Soeteman-Hernandez, Lya G. Wick, Peter Som, Claudia Front Bioeng Biotechnol Bioengineering and Biotechnology Safe-by-Design (SbD) concepts foresee the risk identification and reduction as well as uncertainties regarding human health and environmental safety in early stages of product development. The EU’s NANoREG project and further on the H2020 ProSafe initiative, NanoReg2, and CALIBRATE projects have developed a general SbD approach for nanotechnologies (e.g., paints, textiles, etc.). Based on it, the GoNanoBioMat project elaborated a methodological SbD approach (GoNanoBioMat SbD approach) for nanomedicines with a focus on polymeric nanobiomaterials (NBMs) used for drug delivery. NBMs have various advantages such as the potential to increase drug efficacy and bioavailability. However, the nanoscale brings new challenges to product design, manufacturing, and handling. Nanomedicines are costly and require the combination of knowledge from several fields. In this paper, we present the GoNanoBioMat SbD approach, which allows identifying and addressing the relevant safety aspects to address when developing polymeric NBMs during design, characterization, assessment of human health and environmental risk, manufacturing and handling, and combines the nanoscale and medicine field under one approach. Furthermore, regulatory requirements are integrated into the innovation process. Frontiers Media S.A. 2020-04-02 /pmc/articles/PMC7145422/ /pubmed/32300587 http://dx.doi.org/10.3389/fbioe.2020.00258 Text en Copyright © 2020 Schmutz, Borges, Jesus, Borchard, Perale, Zinn, Sips, Soeteman-Hernandez, Wick and Som. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Bioengineering and Biotechnology Schmutz, Mélanie Borges, Olga Jesus, Sandra Borchard, Gerrit Perale, Giuseppe Zinn, Manfred Sips, Ädrienne A. J. A. M Soeteman-Hernandez, Lya G. Wick, Peter Som, Claudia A Methodological Safe-by-Design Approach for the Development of Nanomedicines |
title | A Methodological Safe-by-Design Approach for the Development of Nanomedicines |
title_full | A Methodological Safe-by-Design Approach for the Development of Nanomedicines |
title_fullStr | A Methodological Safe-by-Design Approach for the Development of Nanomedicines |
title_full_unstemmed | A Methodological Safe-by-Design Approach for the Development of Nanomedicines |
title_short | A Methodological Safe-by-Design Approach for the Development of Nanomedicines |
title_sort | methodological safe-by-design approach for the development of nanomedicines |
topic | Bioengineering and Biotechnology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145422/ https://www.ncbi.nlm.nih.gov/pubmed/32300587 http://dx.doi.org/10.3389/fbioe.2020.00258 |
work_keys_str_mv | AT schmutzmelanie amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT borgesolga amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT jesussandra amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT borchardgerrit amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT peralegiuseppe amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT zinnmanfred amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT sipsadrienneajam amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT soetemanhernandezlyag amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT wickpeter amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT somclaudia amethodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT schmutzmelanie methodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT borgesolga methodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT jesussandra methodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT borchardgerrit methodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT peralegiuseppe methodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT zinnmanfred methodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT sipsadrienneajam methodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT soetemanhernandezlyag methodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT wickpeter methodologicalsafebydesignapproachforthedevelopmentofnanomedicines AT somclaudia methodologicalsafebydesignapproachforthedevelopmentofnanomedicines |